Loading…
NervGen Pharma Corp. is projected to rise to $1.73 by 2027, a +7% move from its current price of $1.62. NGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.57 | $1.62 | $1.67 | +0.05% |
| Aug 5 | $1.55 | $1.62 | $1.69 | +0.09% |
| Aug 6 | $1.54 | $1.62 | $1.71 | +0.14% |
| Aug 7 | $1.53 | $1.62 | $1.72 | +0.18% |
| Aug 8 | $1.52 | $1.62 | $1.74 | +0.23% |
| Aug 9 | $1.51 | $1.62 | $1.75 | +0.27% |
| Aug 10 | $1.50 | $1.63 | $1.76 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.50 | $1.63 | $1.76 | +0.32% |
| Week 2 | $1.45 | $1.63 | $1.83 | +0.63% |
| Week 3 | $1.42 | $1.64 | $1.88 | +0.95% |
| Week 4 | $1.40 | $1.64 | $1.93 | +1.27% |
| Week 5 | $1.37 | $1.65 | $1.97 | +1.59% |
| Week 6 | $1.36 | $1.65 | $2.01 | +1.91% |
| Week 7 | $1.34 | $1.66 | $2.05 | +2.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NervGen Pharma Corp. is a biotechnology company that engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. Its lead product NVG-291 is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300 is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp.
was incorporated in 2017 and is headquartered in Vancouver, Canada.
NervGen Pharma Corp. (NGEN) is currently priced at $1.69 per share with a market cap of $179.84M and a market rank of 3902. The stock trades in a near-term context where technicals show a neutral stance and a defined 30-day range.
The 50-day simple moving average is $2.46 and the 200-day simple moving average is $3.54, with a price support at $1.69 and resistance at $2.20. The 30-day range runs from $1.30 to $2.20, and annualized volatility is 80%. The year-by-year forecast indicates a neutral stance in 2026, transitioning to bullish sentiment from 2028 onward, with rising average prices and ROIs through 2050.
A major floor 26.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 35.8% above — a clean break opens room to run.
A major ceiling 171.0% above — clearing it would confirm fresh momentum.
Key NGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.61 | Buy | $1.62 | Sell |
| MA 10 | $1.66 | Sell | $1.66 | Sell |
| MA 20 | $1.75 | Sell | $1.75 | Sell |
| MA 50 | $1.96 | Sell | $2.12 | Sell |
| MA 100 | $2.93 | Sell | $2.65 | Sell |
| MA 200 | $3.47 | Sell | $2.99 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.97 | Neutral |
| Stoch RSI (14) | 39.54 | Neutral |
| CCI (20) | -74.33 | Neutral |
| Williams %R (14) | -84.21 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.14 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 15.79 | Buy |
| TRIX (15) | -1.00 | Sell |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 24.36 | Buy |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.58 | Buy |
| ADX (14) | 29.34 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 30, a SMA50 of $2.46 and a SMA200 of $3.54. The stock’s immediate trading range over the past 30 days is $1.30 to $2.20. Support is $1.69 and resistance is $2.20, framing a cautious near-term outlook.
Overall, the technicals suggest limited upside near term unless price action moves above the $2.20 resistance or fails below the $1.69 support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $1.62 | $2.11 | 0% | Neutral | |
| $1.36 | $1.73 | $2.32 | +7% | Neutral | |
| $1.62 | $2.12 | $2.98 | +31% | Bullish | |
| $1.77 | $2.37 | $3.43 | +46% | Bullish | |
| $1.93 | $2.65 | $3.94 | +64% | Bullish | |
| $1.91 | $2.69 | $4.09 | +66% | Bullish | |
| $1.70 | $2.44 | $3.78 | +50% | Bullish | |
| $1.92 | $2.80 | $4.43 | +73% | Bullish | |
| $2.17 | $3.23 | $5.20 | +99% | Bullish | |
| $2.35 | $3.56 | $5.82 | +120% | Bullish | |
| $2.70 | $4.40 | $7.71 | +172% | Bullish | |
| $4.40 | $8.23 | $15.86 | +408% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.59 | $1.62 | $1.90 | +0.00% |
| September 2026 | $1.35 | $1.60 | $1.95 | -1.35% |
| October 2026 | $1.41 | $1.69 | $2.09 | +5.62% |
| November 2026 | $1.42 | $1.70 | $2.13 | +0.98% |
| December 2026 | $1.38 | $1.67 | $2.11 | -1.75% |
Click any year to see its month-by-month NGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NGEN price prediction for 2026 points to an average of $1.62 (low $1.59, high $2.11) — a potential gain of 0% on today's $1.62. A consolidation phase looks the most probable path here.
In 2027, NGEN is projected to trade between $1.36 and $2.32, averaging $1.73 — a potential gain of +7% from today's $1.62. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
NervGen Pharma Corp.'s 2028 outlook centres on $2.12, within a $1.62 to $2.98 range. That is up +23% on the projected 2027 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, NGEN could reach as high as $3.43, with a base case around $2.37 and support toward $1.77 — roughly +46% from $1.62. Momentum favours further upside here.
Expect NGEN to range from $1.93 to $3.94 through 2030. The $2.65 average target implies a +64% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The NGEN price prediction for 2031 points to an average of $2.69 (low $1.91, high $4.09) — a potential gain of +66% on today's $1.62. Momentum favours further upside here.
In 2032, NGEN is projected to trade between $1.70 and $3.78, averaging $2.44 — a potential gain of +50% from today's $1.62. That is -9% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
NervGen Pharma Corp.'s 2033 outlook centres on $2.80, within a $1.92 to $4.43 range. That is up +15% on the projected 2032 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2034, NGEN could reach as high as $5.20, with a base case around $3.23 and support toward $2.17 — roughly +99% from $1.62. Buyers look set to stay in control over this stretch.
Expect NGEN to range from $2.35 to $5.82 through 2035. The $3.56 average target implies a +120% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The NGEN price prediction for 2040 points to an average of $4.40 (low $2.70, high $7.71) — a potential gain of +172% on today's $1.62. Buyers look set to stay in control over this stretch.
In 2050, NGEN is projected to trade between $4.40 and $15.86, averaging $8.23 — a potential gain of +408% from today's $1.62. That is up +87% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NGEN today (≈ 617.283951 NGEN) could be worth
$5,080.47
+$4,080.47 (+408%) by 2050 · US Dollar
Based on the average projected NGEN price of $8.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NGENwould be worth at today's price.
$1,000 invested in NGEN on Jul 31, 2025 (≈ 401.767765 NGEN) would be worth
$650.86
-$349.14 (-34.9%) today · 0.65× · US Dollar
Based on a NGEN entry price of $2.49 vs. today's $1.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.63 | $993.87 | -0.6% |
| 1 month ago | $2.09 | $775.12 | -22.5% |
| 3 months ago | $3.78 | $428.57 | -57.1% |
| 6 months ago | $4.18 | $387.56 | -61.2% |
| 1 year ago | $2.49 | $650.86 | -34.9% |
| All time (5.0y) ago | $1.43 | $1,128.92 | +12.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NGEN forecast.
Our base-case forecast reaches $3.20 around 2034.
Implied market cap at $3.20: $340.52M
Across the multi-year forecast, the asset is expected to move from a neutral near-term stance into a bullish longer-term trajectory. In 2026 the min, avg, and max are $1.69, $1.69, and $2.30 with ROI 0 and a NEUTRAL outlook; by 2028 the avg rises to $2.27 with a max of $3.36 and ROI 34.1, accompanied by a BULLISH sentiment. The forecast continues to rise, reaching an average of $2.94 in 2030 with a max of $4.68 and ROI 73.8, and a 2030 sentiment of BULLISH.
The trajectory extends to 2040 with an avg of $4.60 and max of $8.92 (ROI 172.1) and to 2050 with an avg of $8.89 and max of $19.33 (ROI 425.8). These figures imply substantial upside potential over the coming decades, but they remain estimates and come with inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $2.94 with a min of $2.00 and a max of $4.68 and a ROI of 73.8, with a bullish sentiment.
Forecasts indicate a bullish trajectory from 2028 onward, with the avg price rising to $2.27 in 2028, $2.94 in 2030, and $8.89 in 2050, with ROIs of 34.1, 73.8, and 425.8 respectively; however, these are estimates and not guarantees.
Yes. The forecast shows a max of $6.06 in 2034 and $6.96 in 2035, with higher max values in later years (e.g., $8.92 in 2040 and $19.33 in 2050).
Current price is $1.69 and market cap is $179.84M.
NGEN.
NervGen Pharma Corp. Community Discussion
0Share your NervGen Pharma Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.